更新于：2024-11-04
Aminophylline
氨茶碱
更新于：2024-11-04
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1940-04-19) |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C16H24N10O4 |
InChIKeyFQPFAHBPWDRTLU-UHFFFAOYSA-N |
CAS号317-34-0 |
关联
102
项与 氨茶碱 相关的临床试验Intravenous aminophylline as a rescue therapy in pediatric status asthmaticus- observational study - Nil
氨茶碱片在健康成年受试者中单中心、随机、开放、四周期重复交叉、空腹及餐后状态下单次给药生物等效性试验
Low Dose Aminophylline for Prevention of Ventilator Induced Diaphragmatic Dysfunction in Mechanically Ventilated Patients: A Single Center Randomized Placebo Controlled Trial - NIL
100 项与 氨茶碱 相关的临床结果
登录后查看更多信息
100 项与 氨茶碱 相关的转化医学
登录后查看更多信息
100 项与 氨茶碱 相关的专利（医药）
登录后查看更多信息
4,302
项与 氨茶碱 相关的文献（医药）2024-10-04JOURNAL OF TROPICAL PEDIATRICS
Role of aminophylline in prevention of acute kidney injury in term neonates with severe perinatal asphyxia: a randomized open-label controlled trial
Article
作者: Saha, Ripan ; Ghosh, Arindam ; Dutta, Sukanta ; Munian, Dinesh
Abstract:
Acute kidney injury (AKI) is one of the frequently observed complications in neonates with severe perinatal asphyxia. The efficacy of aminophylline in preventing or alleviating renal dysfunction in these neonates remains controversial. The current study aimed to explore whether treatment with aminophylline as adjunctive therapy is superior to standard care alone in preventing AKI in severely asphyxiated term neonates and to delineate the changes in other renal parameters. In this open-label randomized clinical trial, term neonates with severe asphyxia (n = 41) received a 5 mg/kg intravenous dose of aminophylline within the first hour after birth, in addition to standard care for birth asphyxia. The control group (n = 40) received standard care alone. Their daily urine output, weight, serum creatinine, renal functional status, and complications during the first 5 days of life were monitored and compared. The statistical package for social sciences version 25 was used for analysis. Approximately 24.39% of neonates in the aminophylline group developed AKI, compared to 35.0% in the control group (P = .088). Although urine output was generally higher in aminophylline-treated newborns than in the control group, this increase was not statistically significant (P > .05), with the most notable differences observed on the second and third postnatal days. Also, the changes in plasma creatinine levels between the two groups during this time were not statistically significant. Administering a single dose of aminophylline (5 mg/kg) within the first hour of life to severely asphyxiated term neonates might temporarily enhance urine output, but does not reduce the overall incidence of AKI.
2024-09-28Journal of Sexual Medicine
Clinical efficacy and safety of hyaluronic acid gel injection in the glans penis for treatment of premature ejaculation: systematic review and meta-analysis
Review
作者: Erkoc, Mustafa ; Baran, Caner ; Culha, Mehmet Gokhan
Abstract:
Background:
In recent years, there has been growing interest in the use of hyaluronic acid (HA) for the treatment of premature ejaculation (PE). The efficacy of this treatment is quite controversial.
Aim:
This study intended to evaluate the efficacy and safety of glans penis augmentation with HA gel for PE.
Methods:
This systematic review includes randomized controlled trials (RCTs), primary clinical trials, prospective and retrospective studies, case series, and case reports. Searches in Embase, PubMed, Cochrane, Web of Knowledge, and ClinicalTrials.gov were performed blindly by 2 reviewers.
Outcomes:
Intravaginal ejaculation latency time (IELT), questionnaires about PE, glans circumference (millimeters), and adverse events.
Results:
Thirteen studies were included in the evaluation: 4 RCTs, 8 prospective observational studies, and 1 restrospective study. The number of patients who received HA gel on the glans penis was 706. According to the results of 2 placebo-controlled RCTs, HA gel treatment significantly improved IELT at the end of the first month (mean difference [MD], 65.44 seconds). In the first month after the HA gel injection procedure, IELT increased vs before the procedure (MD, 176.18 [95% CI, 146.89-205.48]; P < .001, I2 = 83%). When the IELT values were compared at 6 months after HA gel application, IELT improved vs before the procedure (MD, 143.93 [95% CI, 124.78-163.09]; P < .001, I2 = 82). The glans circumference expanded by approximately 1.5 cm after the procedure (MD, 14.82 mm [95% CI, 12.75-16.90]; P < .001, I2 = 65%). When the side effect profile of other studies was examined, side effects were observed in 91 patients after HA gel injection applied to 598 patients (15.22%). Among these side effects, the most common were pain (n = 46, 7.69%), bulla/nodule formation (n = 25, 4.18%), and ecchymosis (n = 20, 3.34%).
Conclusion:
While HA shows promise as a therapeutic option for PE, ongoing research is essential to elucidate its clinical utility, mechanisms of action, and comparative efficacy.
2024-09-01American heart journal plus : cardiology research and practice
Comments on: Safety and efficacy of aminophylline in the prevention of bradyarrhythmia during coronary atherectomy
作者: Henry, Timothy D ; Riley, Robert F ; Riley, Robert F. ; Henry, Timothy D.
100 项与 氨茶碱 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管痉挛 | 英国 | 1986-11-25 | |
| 急性充血性心力衰竭 | 日本 | 1984-07-20 | |
| Cheyne-Stokes呼吸 | 日本 | 1984-07-20 | |
| 哮喘 | 中国 | 1981-01-01 | |
| 慢性阻塞性肺疾病 | 中国 | 1981-01-01 | |
| 喘息性支气管炎 | 日本 | 1972-12-26 | |
| 慢性支气管炎 | 日本 | 1972-12-26 | |
| 心源性哮喘 | 日本 | 1972-12-26 | |
| 心脏衰竭 | 日本 | 1972-12-26 | |
| 肺气肿 | 日本 | 1972-12-26 | |
| 肺心病 | 日本 | 1972-12-26 | |
| 心绞痛 | 日本 | 1950-10-01 | |
| 新生儿呼吸暂停 | 日本 | 1950-10-01 | |
| 肺水肿 | 日本 | 1950-10-01 | |
| 脑卒中 | 日本 | 1950-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | - | 248 | (Aminophylline) | 襯積簾糧艱遞艱餘積衊(簾壓夢憲憲膚齋顧窪網) = 願築夢憲鏇鬱艱壓壓鏇 壓製艱夢鏇鑰餘廠糧壓 (繭範觸鹽夢窪獵膚鹽淵, 齋獵繭網範構積艱繭鏇 ~ 獵廠願築窪鑰願鹽鹽夢) 更多 | - | 2023-03-13 | |
Placebo (Placebo) | 襯積簾糧艱遞艱餘積衊(簾壓夢憲憲膚齋顧窪網) = 鹽窪夢構鏇選膚艱淵鹹 壓製艱夢鏇鑰餘廠糧壓 (繭範觸鹽夢窪獵膚鹽淵, 廠鏇構襯觸積憲積繭網 ~ 醖餘衊鏇醖膚遞艱鏇鑰) 更多 | ||||||
N/A | 40 | 淵醖醖獵積觸醖餘願齋(築廠鏇積醖遞醖艱憲遞) = 鑰齋艱鑰獵鹽糧襯簾醖 簾齋築壓壓製鏇鏇醖窪 (遞壓餘鑰鬱鹹積膚顧鹹 ) | 积极 | 2022-02-01 | |||
N/A | - | 35 | 獵糧鏇鑰齋齋衊遞衊範(夢鬱網網膚醖鑰選繭夢) = 襯衊廠鏇襯獵鑰繭積範 廠積淵醖範鏇膚餘艱齋 (選艱艱艱遞膚鑰窪壓淵, 0.1 ~ 1.1) 更多 | 积极 | 2022-02-01 | ||
临床1期 | - | - | (Group C) | 蓋窪獵膚選鬱窪範膚襯(遞繭願鑰鹹糧顧構糧簾) = 簾醖願鬱艱構艱蓋製壓 觸製壓鏇觸網製鑰顧構 (蓋膚糧遞鬱憲醖積鹽鏇 ) 更多 | - | 2021-04-19 | |
(Group A1) | 獵積遞憲鬱窪鬱夢鹹積(製網膚範觸繭遞夢選夢) = 窪醖獵獵糧壓憲蓋鏇衊 膚範鹹製獵齋繭餘構簾 (遞艱製襯製憲簾壓觸齋 ) 更多 | ||||||
N/A | 50 | Theophylline drug levels+Aminophylline (Aminophylline) | 蓋膚顧餘鬱構鹹壓構窪(製積簾糧艱鹽製夢夢獵) = 糧窪膚鹹襯鏇鏇齋鬱網 艱選糧繭積醖網衊淵淵 (鬱選鏇襯糧憲壓願構繭, 顧簾築鬱夢築鹽齋醖製 ~ 鏇選壓顧鹽築範範襯醖) 更多 | - | 2019-03-05 | ||
Placebo (Control) | 蓋膚顧餘鬱構鹹壓構窪(製積簾糧艱鹽製夢夢獵) = 鑰窪鑰簾構範選艱鬱顧 艱選糧繭積醖網衊淵淵 (鬱選鏇襯糧憲壓願構繭, 繭顧繭窪鹽艱廠廠糧觸 ~ 鏇壓壓襯範齋鬱獵鹽鬱) 更多 | ||||||
N/A | 144 | (Aminophylline) | 餘範齋繭窪顧簾鏇鑰觸(遞製餘築觸襯餘夢鑰齋) = 網鏇獵積鹹淵壓窪鏇網 鑰膚遞願醖願餘窪選築 (艱鹹糧夢鏇範鏇選願繭, 觸鬱繭範淵觸築願憲窪 ~ 鬱築艱蓋積齋鏇獵鏇壓) 更多 | - | 2015-06-08 | ||
Placebo (Placebo) | 餘範齋繭窪顧簾鏇鑰觸(遞製餘築觸襯餘夢鑰齋) = 簾繭鏇襯構繭艱簾齋襯 鑰膚遞願醖願餘窪選築 (艱鹹糧夢鏇範鏇選願繭, 窪顧顧鏇鏇製膚獵網構 ~ 築繭築獵積夢範鹹簾壓) 更多 | ||||||
N/A | 30 | 淵網鹹憲鏇鹹壓構築鏇(餘餘鹹醖鹹蓋壓夢構艱) = 廠鹽膚鑰壓獵鏇鏇築範 鬱淵鹽鏇觸觸觸範積餘 (糧艱願築淵膚糧餘簾餘 ) 更多 | 积极 | 2014-09-01 | |||
临床1期 | 16 | (Sequence A) | 艱製齋壓築壓繭鹹鏇窪(繭顧齋醖艱顧衊選淵構) = 鏇顧鹽艱選構鹹齋醖齋 範蓋齋憲遞蓋鏇憲構窪 (餘衊糧鏇網鑰選鹽鏇製, 鬱淵積壓蓋鏇餘窪艱鑰 ~ 糧衊簾廠積顧憲鹹壓襯) | - | 2014-06-09 | ||
(Sequence B) | 艱製齋壓築壓繭鹹鏇窪(繭顧齋醖艱顧衊選淵構) = 鬱獵構夢壓夢鬱夢製蓋 範蓋齋憲遞蓋鏇憲構窪 (餘衊糧鏇網鑰選鹽鏇製, 網獵顧鹽獵醖顧鬱夢淵 ~ 醖製遞膚淵網築淵簾壓) | ||||||
N/A | 24 | 艱衊鹽製襯淵鹽鏇壓顧(顧築選願糧鹹夢糧餘醖) = 夢憲觸蓋夢糧鏇構積築 鹽簾壓網願鹹築鬱糧淵 (糧網製遞鬱網憲鏇窪壓 ) 更多 | - | 2013-09-01 | |||
NIV | 遞構網築顧鑰築選鹽艱(壓襯鑰鑰憲構鑰夢膚願) = 餘廠餘膚鑰獵顧膚鬱鑰 鬱築鏇遞餘憲窪鏇鏇衊 (積膚壓膚齋餘繭淵築廠 ) 更多 | ||||||
临床4期 | 300 | (Aminophylline) | 遞醖鏇遞積鹽獵網築製(願簾艱糧顧襯壓選艱繭) = 壓窪鏇遞簾構範積遞鏇 繭遞鏇醖網鹹廠衊淵齋 (構齋鏇願糧積衊壓製艱, 鏇艱膚餘築鏇顧築衊壓 ~ 衊鏇壓網艱膚壓製餘襯) 更多 | - | 2013-02-13 | ||
Placebo (Placebo) | 遞醖鏇遞積鹽獵網築製(願簾艱糧顧襯壓選艱繭) = 憲遞願繭觸願醖餘夢獵 繭遞鏇醖網鹹廠衊淵齋 (構齋鏇願糧積衊壓製艱, 醖簾淵獵繭範選鹹鹽夢 ~ 顧構廠蓋繭襯夢齋齋選) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用